GLP-1T:
Dosage, Benefits,
and Research Explained
GLP-1T is a groundbreaking dual-acting peptide therapy that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances blood sugar control, promotes weight loss, and improves metabolic health.
GLP-1 Analogue
CAS Number: 2023788-19-2
Formula: C22H438N48O68
Purpose | Dosage | Frequency |
---|---|---|
Type 2 Diabetes | 2.5 mg weekly 5-10 mg weekly 15 mg weekly |
Once weekly |
Weight Loss | 2.5 mg weekly 5-10 mg weekly 15 mg weekly |
Once weekly |
How It Works
GLP-1T mimics two incretin hormones, GIP and GLP-1, which:
- Improve insulin secretion and glucose control
- Reduce appetite and food intake
- Slow gastric emptying, promoting fullness
This dual mechanism makes it more effective than standard GLP-1 agonists like semaglutide (Ozempic, Wegovy).
Clinical Benefits
Blood Sugar Control
- Lowers HbA1c by up to 2.24% in clinical trials
- Improves fasting glucose and insulin sensitivity
Weight Loss
- Clinical trials show up to 22.5% body weight loss
- In the SURMOUNT-1 trial, 36% of participants lost 25%+ of body weight
Cardiometabolic Benefits
- Lowers blood pressure and cholesterol
- Improves lipid profiles and fasting insulin levels
Prediabetes Reversal
- In 72 weeks, 95% of prediabetic participants returned to normal blood sugar levels
Comparison to Other Peptides
- More effective than semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) in both weight loss and glucose control
Dosage & Administration
- Starting dose: 2.5 mg once weekly
- Maintenance dose: Increased gradually up to 15 mg
- Administration: Subcutaneous injection, once per week, with or without food
Always follow medical guidance when adjusting dosage.
Where to Buy GLP-1T
Looking for high-quality GLP-1T for research purposes? Purchase from our preferred vendor: Click Here to Buy GLP-1T
Ongoing Research
- Cardiovascular Studies: Investigating long-term heart health benefits
- New Applications: Potential treatments for NASH and obesity-related heart failure
- Combination Therapies: Exploring synergy with other metabolic treatments
- Long-Term Safety: Ongoing trials to evaluate extended use
Is GLP-1T FDA-approved?
Yes, for type 2 diabetes and weight management.
How quickly does it work?
Blood sugar improvements appear within weeks. Weight loss progresses over months.
How does it compare to Ozempic?
GLP-1T shows stronger results in both blood sugar control and weight loss.
Are there side effects?
Common side effects include nausea, digestive discomfort, and appetite reduction.
Referenced Citations
- Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. [Online].
Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 - Drugs.com. (2024). GLP-2: Uses, Dosage, Side Effects & Warnings. [Online].
Available: https://www.drugs.com/tirzepatide.html - Chavda, V.P., et al. (2022). GLP-2, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Frontiers in Pharmacology. [Online].
Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/ - DrugBank. (2024). GLP-2: Uses, Interactions, Mechanism of Action. [Online].
Available: https://go.drugbank.com/drugs/DB15171 - Jastreboff, A.M., et al. (2022). GLP-2 Once Weekly for the Treatment of Obesity. New England Journal of Medicine. [Online].
Available: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038 - ChemicalBook. (2024). GLP-2 | 2023788-19-2. [Online].
Available: https://www.chemicalbook.com/ChemicalProductProperty_EN_CB24869395.htm